Angiogenesis in melanoma: an update with a focus on current targeted therapies

被引:58
作者
Jour, George [1 ]
Ivan, Doina [1 ]
Aung, Phyu P. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 0085,1515 Holcombe Blvd, Houston, TX 77030 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; PRIMARY CUTANEOUS MELANOMA; MATRIX-METALLOPROTEINASE INHIBITOR; METASTATIC MALIGNANT-MELANOMA; VON-WILLEBRAND-FACTOR; PRIMARY TUMOR-GROWTH; STAGE IV MELANOMA; PHASE-II; IN-VIVO; VASCULOGENIC MIMICRY;
D O I
10.1136/jclinpath-2015-203482
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Angiogenesis plays a crucial role in melanoma metastasis and progression. In recent years, numerous studies have investigated the prognostic and clinical significance of this phenomenon, and the development of molecular techniques has enabled us to achieve a better understanding of angiogenesis in melanoma. Herein, we review the current state of knowledge regarding angiogenesis in melanoma, including the pathophysiological, histological and immunohistochemical aspects of this phenomenon. We also review the molecular pathways involved in angiogenesis and the interplay between different components that might be manipulated in the future development of efficient targeted therapies. Recently developed targeted antiangiogenic therapies in clinical trials and included in the treatment of advanced-stage melanoma are also reviewed.
引用
收藏
页码:472 / 483
页数:12
相关论文
共 134 条
  • [1] Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases
    Amaravadi, Ravi K.
    Schuchter, Lynn M.
    McDermott, David F.
    Kramer, Amy
    Giles, Lydia
    Gramlich, Kristi
    Carberry, Mary
    Troxel, Andrea B.
    Letrero, Richard
    Nathanson, Katherine L.
    Atkins, Michael B.
    O'Dwyer, Peter J.
    Flaherty, Keith T.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (24) : 7711 - 7718
  • [2] MicroRNA-mediated regulation of the angiogenic switch
    Anand, Sudarshan
    Cheresh, David A.
    [J]. CURRENT OPINION IN HEMATOLOGY, 2011, 18 (03) : 171 - 176
  • [3] A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth
    AnandApte, B
    Bao, L
    Smith, R
    Iwata, K
    Olsen, BR
    Zetter, B
    Apte, SS
    [J]. BIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE, 1996, 74 (06): : 853 - 862
  • [4] Metronomics: towards personalized chemotherapy?
    Andre, Nicolas
    Carre, Manon
    Pasquier, Eddy
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (07) : 413 - 431
  • [5] Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model
    Arap, W
    Pasqualini, R
    Ruoslahti, E
    [J]. SCIENCE, 1998, 279 (5349) : 377 - 380
  • [6] Microvessel density, lymphovascular density, and lymphovascular invasion in primary cutaneous melanoma-correlation with histopathologic prognosticators and BRAF status
    Aung, Phyu Phyu
    Leone, Dominick
    Feller, John Kyle
    Yang, Shi
    Hernandez, Mailer
    Yaar, Ron
    Singh, Rajendra
    Helm, Thomas
    Mahalingam, Meera
    [J]. HUMAN PATHOLOGY, 2015, 46 (02) : 304 - 312
  • [7] LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan
    Banerji, S
    Ni, J
    Wang, SX
    Clasper, S
    Su, J
    Tammi, R
    Jones, M
    Jackson, DG
    [J]. JOURNAL OF CELL BIOLOGY, 1999, 144 (04) : 789 - 801
  • [8] Expression of platelet-derived growth factor (PDGF)-A, PDGF-B and the PDGF-alpha receptor, but not the PDGF-beta receptor, in human malignant melanoma in vivo
    Barnhill, RL
    Xiao, M
    Graves, D
    Antoniades, HN
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 1996, 135 (06) : 898 - 904
  • [9] BARNHILL RL, 1992, LAB INVEST, V67, P331
  • [10] Bennicelli J L, 1993, Exp Dermatol, V2, P186, DOI 10.1111/j.1600-0625.1993.tb00031.x